Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 2.43
DEPO's Cash to Debt is ranked higher than
76% of the 926 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. DEPO: 2.43 )
DEPO' s 10-Year Cash to Debt Range
Min: 0.84   Max: No Debt
Current: 2.43

Equity to Asset 0.51
DEPO's Equity to Asset is ranked higher than
53% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. DEPO: 0.51 )
DEPO' s 10-Year Equity to Asset Range
Min: -1.33   Max: 0.89
Current: 0.51

-1.33
0.89
Interest Coverage 9.90
DEPO's Interest Coverage is ranked higher than
50% of the 566 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 160.63 vs. DEPO: 9.90 )
DEPO' s 10-Year Interest Coverage Range
Min: 1.73   Max: 9999.99
Current: 9.9

1.73
9999.99
F-Score: 3
Z-Score: 4.64
M-Score: -0.01
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) 60.66
DEPO's Operating margin (%) is ranked higher than
99% of the 875 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.10 vs. DEPO: 60.66 )
DEPO' s 10-Year Operating margin (%) Range
Min: -12972.91   Max: 72.49
Current: 60.66

-12972.91
72.49
Net-margin (%) 33.75
DEPO's Net-margin (%) is ranked higher than
97% of the 875 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.05 vs. DEPO: 33.75 )
DEPO' s 10-Year Net-margin (%) Range
Min: -14964.35   Max: 75.05
Current: 33.75

-14964.35
75.05
ROE (%) 59.62
DEPO's ROE (%) is ranked higher than
99% of the 895 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.83 vs. DEPO: 59.62 )
DEPO' s 10-Year ROE (%) Range
Min: -1132.2   Max: 539.95
Current: 59.62

-1132.2
539.95
ROA (%) 22.80
DEPO's ROA (%) is ranked higher than
97% of the 930 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.82 vs. DEPO: 22.80 )
DEPO' s 10-Year ROA (%) Range
Min: -201.37   Max: 73.87
Current: 22.8

-201.37
73.87
ROC (Joel Greenblatt) (%) 3012.48
DEPO's ROC (Joel Greenblatt) (%) is ranked higher than
100% of the 925 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.02 vs. DEPO: 3012.48 )
DEPO' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2396.53   Max: 7997.51
Current: 3012.48

-2396.53
7997.51
Revenue Growth (3Y)(%) 35.50
DEPO's Revenue Growth (3Y)(%) is ranked higher than
86% of the 742 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.40 vs. DEPO: 35.50 )
DEPO' s 10-Year Revenue Growth (3Y)(%) Range
Min: -69.7   Max: 420.5
Current: 35.5

-69.7
420.5
EBITDA Growth (3Y)(%) 43.20
DEPO's EBITDA Growth (3Y)(%) is ranked higher than
96% of the 676 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.40 vs. DEPO: 43.20 )
DEPO' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -55.8   Max: 84.2
Current: 43.2

-55.8
84.2
EPS Growth (3Y)(%) 16.50
DEPO's EPS Growth (3Y)(%) is ranked higher than
99% of the 667 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.10 vs. DEPO: 16.50 )
DEPO' s 10-Year EPS Growth (3Y)(%) Range
Min: -59.5   Max: 180.9
Current: 16.5

-59.5
180.9
» DEPO's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

DEPO Guru Trades in Q1 2014

Paul Tudor Jones 63,632 sh (+220.52%)
Jim Simons Sold Out
Steven Cohen 17,403 sh (-99.07%)
» More
Q2 2014

DEPO Guru Trades in Q2 2014

Joel Greenblatt 937,085 sh (New)
George Soros 75,600 sh (New)
Paul Tudor Jones 40,112 sh (-36.96%)
» More
Q3 2014

DEPO Guru Trades in Q3 2014

Steven Cohen 448,900 sh (New)
Joel Greenblatt 1,637,713 sh (+74.77%)
Paul Tudor Jones 64,690 sh (+61.27%)
George Soros Sold Out
» More
Q4 2014

DEPO Guru Trades in Q4 2014

Joel Greenblatt 1,218,263 sh (-25.61%)
Paul Tudor Jones 42,365 sh (-34.51%)
Steven Cohen 151,800 sh (-66.18%)
» More
» Details

Insider Trades

Latest Guru Trades with DEPO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Joel Greenblatt 2014-12-31 Reduce -25.61%0.06%$14.05 - $16.37 $ 22.9951%1218263
Joel Greenblatt 2014-09-30 Add 74.77%0.11%$10.69 - $15.49 $ 22.9972%1637713
George Soros 2014-09-30 Sold Out 0.01%$10.69 - $15.49 $ 22.9972%0
Joel Greenblatt 2014-06-30 New Buy0.16%$10.57 - $14.37 $ 22.9979%937085
George Soros 2014-06-30 New Buy0.01%$10.57 - $14.37 $ 22.9979%75600
Joel Greenblatt 2012-06-30 Sold Out 0.01%$4.97 - $6.6 $ 22.99305%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 13.00
DEPO's P/E(ttm) is ranked higher than
93% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 48.60 vs. DEPO: 13.00 )
DEPO' s 10-Year P/E(ttm) Range
Min: 2.36   Max: 121.85
Current: 13

2.36
121.85
Forward P/E 15.90
DEPO's Forward P/E is ranked higher than
91% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 58.14 vs. DEPO: 15.90 )
N/A
PE(NRI) 12.70
DEPO's PE(NRI) is ranked higher than
93% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 48.50 vs. DEPO: 12.70 )
DEPO' s 10-Year PE(NRI) Range
Min: 2.36   Max: 123.38
Current: 12.7

2.36
123.38
P/B 3.70
DEPO's P/B is ranked higher than
72% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.57 vs. DEPO: 3.70 )
DEPO' s 10-Year P/B Range
Min: 2   Max: 48.18
Current: 3.7

2
48.18
P/S 4.00
DEPO's P/S is ranked higher than
67% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.01 vs. DEPO: 4.00 )
DEPO' s 10-Year P/S Range
Min: 1.38   Max: 752
Current: 4

1.38
752
EV-to-EBIT 3.38
DEPO's EV-to-EBIT is ranked higher than
94% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 35.09 vs. DEPO: 3.38 )
DEPO' s 10-Year EV-to-EBIT Range
Min: -208.4   Max: 130
Current: 3.38

-208.4
130
Shiller P/E 47.20
DEPO's Shiller P/E is ranked higher than
77% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 103.75 vs. DEPO: 47.20 )
DEPO' s 10-Year Shiller P/E Range
Min: 21.62   Max: 123.75
Current: 47.2

21.62
123.75
Current Ratio 10.74
DEPO's Current Ratio is ranked higher than
96% of the 900 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.36 vs. DEPO: 10.74 )
DEPO' s 10-Year Current Ratio Range
Min: 0.29   Max: 12.5
Current: 10.74

0.29
12.5
Quick Ratio 10.59
DEPO's Quick Ratio is ranked higher than
96% of the 900 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.83 vs. DEPO: 10.59 )
DEPO' s 10-Year Quick Ratio Range
Min: 0.29   Max: 12.5
Current: 10.59

0.29
12.5
Days Inventory 203.24
DEPO's Days Inventory is ranked higher than
63% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 153.90 vs. DEPO: 203.24 )
DEPO' s 10-Year Days Inventory Range
Min: 93.22   Max: 613.73
Current: 203.24

93.22
613.73
Days Sales Outstanding 25.25
DEPO's Days Sales Outstanding is ranked higher than
95% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 94.97 vs. DEPO: 25.25 )
DEPO' s 10-Year Days Sales Outstanding Range
Min: 12.13   Max: 54004.13
Current: 25.25

12.13
54004.13

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 4.64
DEPO's Price/Tangible Book is ranked higher than
74% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.29 vs. DEPO: 4.64 )
DEPO' s 10-Year Price/Tangible Book Range
Min: 2.54   Max: 87
Current: 4.64

2.54
87
Earnings Yield (Greenblatt) 29.60
DEPO's Earnings Yield (Greenblatt) is ranked higher than
94% of the 927 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. DEPO: 29.60 )
DEPO' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.8   Max: 251.9
Current: 29.6

0.8
251.9

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:DPO.Germany,
Depomed, Inc., was incorporated in the State of California on August 7, 1995. The Company is a specialty pharmaceutical company focused on pain and other conditions and diseases of the central nervous system. The Products that comprise its specialty pharmaceutical business are Gralise, Zipsor (diclofenac potassium) liquid filled capsules, its non-steriodal anti-inflammatory drug for the treatment of mild to moderate acute pain, CAMBIA, its non-steriodal anti-inflammatory drug for the acute treatment of migraine attacks, and Lazanda nasal spray, its product for the management of breakthrough pain in cancer patients 18 years of age and older who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. The Company's operation and business are subject to a number of other laws and regulations, including those relating to the workplace, privacy, laboratory practices and the purchase, storage, movement, import and export and use and disposal of hazardous or potentially hazardous substances as well as controlled substances.
» More Articles for DEPO

Headlines

Articles On GuruFocus.com
5 Healthcare Picks for 2012 Mar 21 2012 
Depomed Inc. Reports Operating Results (10-K) Mar 16 2011 
Depomed Inc. Reports Operating Results (10-Q) Aug 06 2010 
Depomed Inc. Reports Operating Results (10-Q) May 04 2010 
Depomed Inc. Reports Operating Results (10-Q) Aug 07 2009 
Depomed Reports Second Quarter 2009 Financial Results Jul 30 2009 
Depomed Inc. Reports Operating Results (10-Q) May 06 2009 

More From Other Websites
Depomed To Present At 27th Annual Roth Conference Mar 03 2015
10-K for Depomed, Inc. Feb 28 2015
DEPOMED INC Files SEC form 10-K, Annual Report Feb 26 2015
Depomed Reports Fourth Quarter and Full Year 2014 Financial Results Feb 25 2015
The Nasdaq is doing the most bullish thing a market can do Feb 24 2015
Depomed: The Next Big Specialty Pharma Success Story Feb 24 2015
Stocks Mixed As Yellen Speaks; Depomed, Home Depot, BHP Surge Feb 24 2015
Depomed tops 4Q revenue forecasts Feb 23 2015
Depomed tops 4Q revenue forecasts Feb 23 2015
DEPOMED INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements... Feb 23 2015
Depomed Inc Earnings Call scheduled for 4:30 pm ET today Feb 23 2015
Depomed Reports Fourth Quarter and Full Year 2014 Financial Results Feb 23 2015
Q4 2014 Depomed Inc Earnings Release - After Market Close Feb 23 2015
Two young stocks poised for a growth spurt Feb 19 2015
Depomed To Report Fourth Quarter Fiscal Year 2014 Financial Results On Monday, February 23, 2015 Feb 12 2015
New American Headache Society Assessment of Acute Migraine Treatments Highlights Effective Therapies... Feb 09 2015
DEPOMED INC Files SEC form 8-K, Change in Directors or Principal Officers, Amendment or Waiver to... Feb 06 2015
Depomed To Present At Healthcare Conferences In February Feb 04 2015
East Bay's Depomed snags J&J pain-fighting drug in $1 billion deal Jan 20 2015
U.S. markets break 5-day losing streak Jan 16 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK